* Announced on Sunday safety data for two Phase I studies
conducted by Bristol-Myers Squibb
The post BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab appeared first on NASDAQ.
BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab
